Abstract Background and Purpose Cannabis has been used to treat epilepsy for millennia, with such use validated by regulatory approval of cannabidiol (CBD) for Dravet syndrome. Unregulated artisanal cannabis-based products
Abstract Epilepsy is one of the most common neurological conditions worldwide. Cannabinoids, particularly cannabidiol (CBD) and tetrahydrocannabinol (THC), have demonstrated therapeutic potential in the treatment of epilepsy due to their
Highlights Prospective study with sleep and mood assessment in people with epilepsy (PWE) reporting cannabis use. Self-reported sleep quality, but not sleep quality and quantity from PSG was significantly better
Summary Objective To assess the benefits and harms of cannabis-based products for pediatric epilepsy. Methods We identified in this living systematic review randomized controlled trials (RCTs) and nonrandomized studies (NRSs)
Our collective knowledge of the benefits of the cannabis plant for epilepsy continues to increase year after year. In addition to seizure reduction, we have learned through the literature that
Please use this link to access this publication. Abstract Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been
Abstract Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom;
Please use this link to access this publication. Abstract Purpose of Review For millennia, there has been interest in the use of cannabis for the treatment of epilepsy. However, it is only
Abstract Epilepsy Action Australia conducted an Australian nationwide online survey seeking opinions on and experiences with the use of cannabis-based products for the treatment of epilepsy. The survey was promoted via
Summary Objective Tuberous sclerosis complex (TSC) is an autosomal-dominant genetic disorder with highly variable expression. The most common neurologic manifestation of TSC is epilepsy, which affects approximately 85% of patients,
